China Listed Bio-pharmaceutical Companies Report, 2008
  • May/2009
  • Hard Copy
  • USD $1,500
  • Pages:98
  • Single User License
    (PDF Unprintable)       
  • USD $1,600
  • Code: HJ005
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,400
  • Hard Copy + Single User License
  • USD $1,700

This report firstly gives an overview of China bio-pharmaceutical industry, and then analyses sub-industries, import & exports status of the industry; finally it expounds the operations and revenue, project investment, main business structure, latest development and future trend of key 20 bio-pharmaceutical companies.

Sales revenue of bio-pharmaceutical industry in Jan-Nov 2008 raised 29.8% compared with the same period of 2007, up 7.6 points; Sales cost saw a 33.9% YoY rise; and gross profit margin grew 28.2% year-on-year, down 2.5 percentage points. The rate of period expense was 15.8%, down 1.2 points from the same period of 2007.

In 2008, China exported 1,632.14 tons of human & animal blood products, antiserum and vaccines, down 29.7% year on year; the export value totaled US$56.92 million, down 85.3%; the export price per unit was US$34.87/kg, US$16.96/kg lower than 2007.

In addition, the import volume of human & animal blood products, antiserum and vaccines amounted to 8,977.90 tons, up 2.87 times; the import value totaled US$558.16 million, up 44.3%; unit import price was US$62.17/kg, US$167.37/kg lower than 2007.

Taking Hualan Biological Engineering Inc. as an example:

Revenue and Net Profit of Hualan Biological Engineering Inc., 2003-2008

Revenue Structure By Product of Hualan Biological Engineering Inc., 2008

1.Overview of China Bio-pharmaceutical Industry, 2008
1.1 Industry Development
1.2 Market 
1.2.1 Overview
1.2.2 Sub-industries
1.2.3 Import & Export

2. Shenzhen CAU Technology Co., Ltd (000004)
2.1 Company Profile
2.2 Operations and Revenue
2.3 Investment
2.4 Main Business Structure
2.5 Latest Development and Future Trend

3.Shenzhen Neptunus Bioengineering Co., Ltd (000078)
3.1 Company Profile
3.2 Operations and Revenue
3.3 Investment
3.4 Main Business Structure
3.5 Latest Development and Future Trend

4.Sihuan Pharmaceutical Co., Ltd (000605)
4.1 Company Profile
4.2 Operations and Revenue
4.3 Investment
4.4 Main Business Structure
4.5 Latest Development and Future Trend

5.Changchun High & New Technology Industries (Group) Inc. (000661)
5.1 Company Profile
5.2 Operations and Revenue
5.3 Investment
5.4 Main Business Structure
5.5 Latest Development and Future Trend

6.Chengzhi Co., Ltd (000990)
6.1 Company Profile
6.2 Operations and Revenue
6.3 Investment
6.4 Main Business Structure
6.5 Latest Development and Future Trend

7. Hualan Biological Engineering Inc.(002007)
7.1 Company Profile
7.2 Operations and Revenue
7.3 Investment
7.4 Main Business Structure
7.5 Latest Development and Future Trend

8.Shanghai Kehua Bio-engineering Co., Ltd (002022)
8.1 Company Profile
8.2 Operations and Revenue
8.3 Investment
8.4 Main Business Structure
8.5 Latest Development and Future Trend

9.Da An Gene Co., Ltd (002030)
9.1 Company Profile
9.2 Operations and Revenue
9.3 Investment
9.4 Main Business Structure
9.5 Latest Development and Future Trend

10.Beijing SL Pharmaceutical Co., Ltd (002038)
10.1 Company Profile
10.2 Operations and Revenue
10.3 Investment
10.4 Main Business Structure
10.5 Latest Development and Future Trend

11.Shanghai RAAS Blood Products Co., Ltd (002252)
11.1 Company Profile
11.2 Operations and Revenue
11.3 Investment
11.4 Main Business Structure
11.5 Latest Development and Future Trend

12.Ginwa Enterprise (Group) Co., Ltd (600080)
12.1 Company Profile
12.2 Operations and Revenue
12.3 Investment
12.4 Main Business Structure
12.5 Latest Development and Future Trend

13.Beijing Tiantan Biological Products Co., Ltd (600161)
13. 1 Company Profile
13.2 Operations and Revenue
13.3 Investment
13.4 Main Business Structure
13.5 Latest Development and Future Trend

14.China Animal Husbandry Industry Co., Ltd (600195)
14.1 Company Profile
14.2 Operations and Revenue
14.3 Investment
14.4 Main Business Structure
14.5 Latest Development and Future Trend

15.Shanghai Fosun Pharmaceutical (Group) Co., Ltd (600196)
15.1 Company Profile
15.2 Operations and Revenue
15.3 Investment
15.4 Main Business Structure
15.5 Latest Development and Future Trend

16.Inner Mongolia Jinyu Group Co., Ltd (600201)
16.1 Company Profile
16.2 Operations and Revenue
16.3 Investment
16.4 Main Business Structure
16.5 Latest Development and Future Trend

17.Shanghai Jiao Da Onlly Co., Ltd (600530)
17.1 Company Profile
17.2 Operations and Revenue
17.3 Investment
17.4 Main Business Structure
17.5 Latest Development and Future Trend

18.Beihai Gofar Marine Biological Industry Co., Ltd (600538)
18.1 Company Profile
18.2 Operations and Revenue
18.3 Investment
18.4 Main Business Structure
18.5 Latest Development and Future Trend

19.Zhongyuan Union Stem Cell Bioengineering Co., Ltd (600645)
19.1 Company Profile
19.2 Operations and Revenue
19.3 Investment
19.4 Main Business Structure
19.5 Latest Development and Future Trend

20.Star Lake Bioscience Co., Inc (600866)
20.1 Company Profile
20.2 Operations and Revenue
20.3 Investment
20.4 Main Business Structure
20.5 Latest Development and Future Trend

21.Tonghua Dongbao Pharmaceutical Co., Ltd (600867)
21.1 Company Profile
21.2 Operations and Revenue
21.3 Main Business Structure
21.4 Latest Development and Future Trend
Growth of Quarterly Revenue of Bio-pharmaceutical Industry, 2005Q1-2009Q1
Growth of Quarterly Total Profit of Bio-pharmaceutical Industry, 2005Q1-2009Q1
YoY Growth Rate of Sales Revenue and Total profit of Bio-pharmaceutical Industry, Jan-Nov 2008
Gross Profit Margin and Pre-tax Margin of Bio-pharmaceutical Industry, Jan-Nov2008
Top Six Immune Vaccines In Terms of Planned Investment in China 
Market Share of MMR Triple Vaccine in China, 2007 Market Share of Influenza Vaccine in China, 2007
Market Share of Antineoplastics in China 
Market Share of Plant-based Antitumor Drugs in China 
Rank of China’s Docetaxel Producers
Import of China’s Human & Animal Blood Products, Antiserum and Vaccine, Jan-Dec 2008
Export of China’s Human & Animal Blood Products, Antiserum and Vaccine, Jan-Dec 2008
Revenue and Net Profit of Shenzhen CAU Technology Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Shenzhen CAU Technology Co., Ltd, 2003-2008
Revenue Structure of Shenzhen CAU Technology Co., Ltd by Product, 2008
Revenue Structure of Shenzhen CAU Technology Co., Ltd by Sector, 2008
Revenue Structure of Shenzhen CAU Technology Co., Ltd by Region, 2008
Revenue and Net Profit of Shenzhen Neptunus Bioengineering Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Shenzhen Neptunus Bioengineering Co., Ltd, 2003-2008
Revenue Structure of Shenzhen Neptunus Bioengineering Co., Ltd by Sector, 2008
Revenue and Net Profit of Sihuan Pharmaceutical Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Sihuan Pharmaceutical Co., Ltd, 2003-2008
Revenue Structure of Sichuan Pharmaceutical Co., Ltd by Product, 1H 2008
Revenue and Net Profit of Changchun High & New Technology Industries (Group) Inc., 2003-2008
Total Asset and Monetary Capital Changchun High & New Technology Industries (Group) Inc., 2003-2008
Revenue Structure of Changchun High & New Technology Industries (Group) Inc. by Product, 2008
Indices of Main Business Revenue, Cost and Gross Profit Margin of Changchun High & New Technology Industries (Group) Inc., 2008
Operating Profit Proportion of Changchun High & New Technology Industries (Group) Inc., 2008
Revenue and Net Profit of Chengzhi Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Chengzhi Co., Ltd, 2003-2008
Revenue Structure of Chengzhi Co., Ltd by Sector, 2008
Revenue Structure of Chengzhi Co., Ltd by Business, 2007-2008
Quarterly Revenue and Growth Rate of Profit of Chengzhi Co., Ltd, 2008
Shareholding Structure of Hualan Biological Engineering Inc.
Revenue and Net Profit of Hualan Biological Engineering Inc., 2003-2008 Total Asset and Monetary Capital of Hualan Biological Engineering Inc., 2003-2008 Revenue Structure of Hualan Biological Engineering Inc. by Product, 2008
Issued Quantity Proportion of Influenza Vaccines in China, 2008
Issued Quantity of Influenza Vaccines in China, 2007-2008
Issued Quantity Proportion of Hepatitis B Vaccines in China, 2008
Issued Quantity Proportion of ACYW135 Vaccine of Hualan Biological Engineering Inc., 2008
Revenue and Net Profit of Shanghai Kehua Bio-engineering Co., Ltd 2003-2008
Total Asset and Monetary Capital of Shanghai Kehua Bio-engineering Co., Ltd, 2003-2008
Revenue Structure of Shanghai Kehua Bio-engineering Co., Ltd by Product, 2008
Sales Growth of Hepatitis Immune Products of Shanghai Kehua Bio-engineering Co., Ltd, 2005-2008
Net Profit Margin of Hepatitis Immune Products of Shanghai Kehua Bio-engineering Co., Ltd,  2005-2008
Apparatus Sales Ratio of Shanghai Kehua Bio-engineering Co. increased from 2005-2008 
Revenue and Net Profit of Da An Gene Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Da An Gene Co., Ltd, 2003-2008
Revenue Structure of Da An Gene Co., Ltd by Product, 2008
China In-Vitro Diagnostics Sub-industries, 2008 
Revenue and Net Profit of Beijing SL Pharmaceutical Co., Ltd, 2003-2008
Total Asset and Monetary Capital Beijing SL Pharmaceutical Co., Ltd, 2003-2008
Revenue Structure of Beijing SL Pharmaceutical Co., Ltd by Product, 2008
Quarterly Revenue and Net Profit of Beijing SL Pharmaceutical Co., Ltd, 2005-2008
Quarterly Profitability of Beijing SL Pharmaceutical Co., Ltd, 2005-2008 
Revenue and Net Profit of Shanghai RAAS Blood Products Co., Ltd, 2005-2008
Total Asset and Monetary Capital of Shanghai RAAS Blood Products Co., Ltd, 2005-2008
Revenue Structure of Shanghai RAAS Blood Products Co., Ltd by Product, 2008
Sales by Product of Shanghai RAAS Blood Products Co., Ltd, 2007-2008
Sales Gross Profit Margin of Shanghai RAAS Blood Products Co., Ltd, 2008
Revenue from HSA and Intravenous Gammaglobulin, 2005-2008
Changes of Plasma Circulation in China
Revenue and Net Profit of Ginwa Enterprise (Group) Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Ginwa Enterprise (Group) Co., Ltd, 2003-2008
Revenue Structure by Sector of Ginwa Enterprise (Group) Co., Ltd, 2008
Revenue and Net Profit of Beijing Tiantan Biological Products Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Beijing Tiantan Biological Products Co., Ltd, 2003-2008
Revenue Structure of Beijing Tiantan Biological Products Co., Ltd by Product, 2008
Sales of Vaccine & Blood Products of Beijing Tiantan Biological Products Co., Ltd, 2006-2008
Issued Quantity of MMR Triple Vaccines of Beijing Tiantan Biological Products Co., Ltd, 2008-2009Q1
Issued Quantity of  Hepatitis B Vaccines of Beijing Tiantan Biological Products Co., Ltd, 2008-2009Q1
Product Structure of Chengdu Rongsheng Pharmaceuticals Co., Ltd before It Was Purchased 
Issued Quantity of HAS in China, 2008 Issued Quantity of Intravenous Gammaglobulin in China, 2008
Revenue and Net Profit of China Animal Husbandry Industry Co., Ltd, 2003-2008
Total Asset and Monetary Capital of China Animal Husbandry Industry Co., Ltd, 2003-2008
Revenue Structure of China Animal Husbandry Industry Co., Ltd by Sector, 2008
Revenue Structure of China Animal Husbandry Industry Co., Ltd, 2004-2008
Main Operating Profit Structure of China Animal Husbandry Industry Co., Ltd, 2004-2008
Main Operating Profit Rate of China Animal Husbandry Industry Co. by Product, 2004-2008
Key Immune Solutions to Animal Epidemic Issued by China Ministry of Agriculture, 2009 
Revenue and Net Profit of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, 2003-2008
Revenue Structure of Shanghai Fosun Pharmaceutical (Group) Co., Ltd by Product, 2008
Quarterly Performance of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, 2007-2008
Main Business Revenue Proportion of Shanghai Fosun Pharmaceutical (Group) Co., 2008
Main Business Profit Proportion of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, 2008
Performances of Main Businesses Shanghai Fosun Pharmaceutical (Group) Co., Ltd, 2004-2008
Revenue and Net Profit of Inner Mongolia Jinyu Group Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Inner Mongolia Jinyu Group Co., Ltd, 2003-2008
Revenue Structure of Inner Mongolia Jinyu Group Co., Ltd by Product, 2008
Main Business Revenue Structure of Inner Mongolia Jinyu Group Co., Ltd, 2005-2008
Main Business Profit Structure of Inner Mongolia Jinyu Group Co., Ltd, 2005-2008
Revenue form Animal Vaccine and Main operating Profit Rate of Inner Mongolia Jinyu Group Co., Ltd, 2005-2008
Revenue and Net Profit of Shanghai Jiao Da Onlly Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Shanghai Jiao Da Onlly Co., Ltd, 2003-2008
Revenue Structure of Shanghai Jiao Da Onlly Co., Ltd by Sector, 2008
Revenue and Net Profit of Beihai Gofar Marine Biological Industry Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Beihai Gofar Marine Biological Industry Co., Ltd 2003-2008
Revenue Structure of Beihai Gofar Marine Biological Industry Co., Ltd by Sector, 2008
Revenue and Net Profit of Zhongyuan Union Stem Cell Bioengineering Co., Ltd 2003-2008
Total Asset and Monetary Capital of Zhongyuan Union Stem Cell Bioengineering Co., Ltd 2003-2008
Revenue Structure by Sector of Zhongyuan Union Stem Cell Bioengineering Co., Ltd, 2008
Revenue and Net Profit of Star Lake Bioscience Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Star Lake Bioscience Co., Ltd, 2003-2008
Revenue Structure of Star Lake Bioscience Co., Ltd by Product, 2008
Shareholding Structure of Tonghua Dongbao Pharmaceutical Co., Ltd.
Revenue and Net Profit of Tonghua Dongbao Pharmaceutical Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Tonghua Dongbao Pharmaceutical Co., Ltd, 2003-2008
Revenue Structure of Tonghua Dongbao Pharmaceutical Co. by Product, 2008
Sales and Profitability Analysis by Products of Tonghua Dongbao Pharmaceutical Co., Ltd, 2007-2008
Revenue from Recombinant Human Insulin of Tonghua Dongbao Pharmaceutical Co., Ltd, 2005-2008
Revenue Proportion of Recombinant Human Insulin Tonghua Dongbao Pharmaceutical Co., Ltd, 2005-2008
Net Profit and Asset of Key Subsidiary Companies of Tonghua Dongbao Pharmaceutical Co., Ltd, 2004-2008

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

Global and China Monoclonal Antibody Industry Report, 2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

Global and China Industrial Enzyme Industry Report, 2012-2014

Industrial enzyme which refers to the enzyme preparation used for industrial purposes can be applied to detergent, animal feed, bread, brewing (beer, wine, etc.), papermaking, textile, bio-ethanol and...

China Blood Products Industry Report, 2011-2012

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号